Repligen Corporation
NASDAQ:RGENMedical - Instruments & Supplies
-$3.66 today
- Market cap
- $11.04B
- Beta
- 1.08
- P/E (TTM)
- 142.4
- EPS (TTM)
- $0.91
Volume 1.30M
Average 1.08M
RGEN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Repligen CorporationNASDAQ: RGEN
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $8.01M fell 4.3% year over year, ahead of the -26.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Stock-based compensation amounted to 4.4% of revenue in FY2025, down 3.2 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -4.3% holds above the trailing-twelve-month pace of -26.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 32.61M USD
- Year-over-year change
- -32.2%
- 4-year CAGR
- +4.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.61M | -32.2% |
| FY2024 | 2024-12-31 | 48.07M | +88.0% |
| FY2023 | 2023-12-31 | 25.58M | -6.4% |
| FY2022 | 2022-12-31 | 27.32M | -0.7% |
| FY2021 | 2021-12-31 | 27.5M | — |
Stock-Based Compensation vs competitors
How RGEN compares with its peers on the latest reported figures
- RGEN's LTM Jun 2026 stock-based compensation of $33.29M is the 7th largest of the 9 companies compared; the peer median is $42.8M.
- Its year-over-year change of -26.1% is the 7th highest of 8, against a peer median of -13.6%.
- Stock-based compensation amounts to 4.2% of revenue for RGEN, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $131M | +2.3% | +0.8% | 1.8% | |
| LTM Sep 2026 | $84M | — | +0.3% | 0.2% | |
| LTM Jun 2026 | $45.8M | +43.1% | -1.6% | 1.8% | |
| LTM Sep 2026 | $43.09M | +56.0% | +1.8% | 3.5% | |
| LTM Jun 2026 | $42.5M | -16.5% | +0.4% | 0.6% | |
| LTM Jun 2026 | $36.96M | -13.6% | +0.6% | 1.8% | |
| LTM Jun 2026 | $33.29M | -26.1% | +6.1% | 4.2% | |
| LTM Jun 2026 | $26M | -36.2% | — | 12.5% | |
| LTM Mar 2026 | $23.65M | -18.2% | -3.2% | 23.7% | |
| Peer median (excluding RGEN) | $42.8M | -13.6% | +0.4% | 1.8% | |
Competitors are the stored peer set for RGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 128.29M | 185.96M | 41.58M | (25.51M) | 48.89M |
| Depreciation & Amortization | 38.45M | 57.01M | 86.11M | 86.56M | 96.96M |
| Deferred Income Tax | 6.52M | (1.35M) | 2.32M | (16.79M) | (3.37M) |
| Stock-Based Compensation | 27.5M | 27.32M | 25.58M | 48.07M | 32.61M |
| Change in Working Capital | (102.13M) | (69.84M) | (8.64M) | 60.92M | (50.88M) |
| Accounts Receivables | (46.53M) | (3.6M) | (3.31M) | (14.03M) | (17.17M) |
| Inventory | (89.78M) | (57.2M) | 40.97M | 56.9M | (14.95M) |
| Accounts Payables | 19.52M | (8.2M) | (9.8M) | 12.9M | (4.15M) |
| Other Working Capital | 14.66M | (841K) | (36.5M) | 5.16M | (14.62M) |
| Other Non-Cash Items | 20.39M | (27.01M) | (33.03M) | 22.15M | (6.79M) |
| Operating Cash Flow | 119.02M | 172.08M | 113.92M | 175.39M | 117.42M |
| Capital Expenditures | (67.09M) | (133.35M) | (38.99M) | (32.91M) | (23.52M) |
| Acquisitions (Net) | (149.89M) | 0 | (186.64M) | (54.77M) | (70.33M) |
| Purchases of Investments | 0 | (100M) | 0 | 0 | (200.26M) |
| Sales of Investments | 0 | 0 | 102.32M | 0 | 0 |
| Other Investing Activities | (4.19M) | (48.4M) | (2.73M) | (5.94M) | (4.37M) |
| Investing Cash Flow | (221.17M) | (233.24M) | (123.28M) | (86.38M) | (298.47M) |
| Debt Repayment | (21K) | 0 | 290.09M | (69.94M) | 0 |
| Common Stock Issued | 3.88M | 3.71M | 1.08M | 4.29M | 3.18M |
| Common Stock Repurchased | 0 | 0 | (14.39M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.9M) | (17.04M) | (27.82M) | (17.26M) | (18.38M) |
| Financing Cash Flow | 961K | (13.34M) | 248.96M | (82.9M) | (15.21M) |
| Effect of Forex Changes | (12.29M) | (5.87M) | (11.74M) | (77K) | 4.93M |
| Net Change in Cash | (113.48M) | (80.36M) | 227.87M | 6.03M | (191.33M) |
| Free Cash Flow | 51.93M | 38.74M | 74.93M | 142.49M | 93.9M |
Repligen Corporation
NASDAQ:RGEN
Intrinsic Alpha fair value
Locked
Current Price
$172.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.